PMID- 37190200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230801
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 8
DP  - 2023 Apr 13
TI  - Molecular Insights of MAP4K4 Signaling in Inflammatory and Malignant Diseases.
LID - 10.3390/cancers15082272 [doi]
LID - 2272
AB  - Mitogen-activated protein kinase (MAPK) cascades are crucial in extracellular 
      signal transduction to cellular responses. The classical three-tiered MAPK 
      cascades include signaling through MAP kinase kinase kinase (MAP3K) that 
      activates a MAP kinase kinase (MAP2K), which in turn induces MAPK activation and 
      downstream cellular responses. The upstream activators of MAP3K are often small 
      guanosine-5'-triphosphate (GTP)-binding proteins, but in some pathways, MAP3K can 
      be activated by another kinase, which is known as a MAP kinase kinase kinase 
      kinase (MAP4K). MAP4K4 is one of the widely studied MAP4K members, known to play 
      a significant role in inflammatory, cardiovascular, and malignant diseases. The 
      MAP4K4 signal transduction plays an essential role in cell proliferation, 
      transformation, invasiveness, adhesiveness, inflammation, stress responses, and 
      cell migration. Overexpression of MAP4K4 is frequently reported in many cancers, 
      including glioblastoma, colon, prostate, and pancreatic cancers. Besides its 
      mainstay pro-survival role in various malignancies, MAP4K4 has been implicated in 
      cancer-associated cachexia. In the present review, we discuss the functional role 
      of MAP4K4 in malignant/non-malignant diseases and cancer-associated cachexia and 
      its possible use in targeted therapy.
FAU - Singh, Sunil Kumar
AU  - Singh SK
AUID- ORCID: 0000-0001-7639-9212
AD  - Department of Surgery, Division of Surgical Oncology, University of Illinois at 
      Chicago, Chicago, IL 60612, USA.
FAU - Roy, Ruchi
AU  - Roy R
AD  - UICentre for Drug Discovery, University of Illinois at Chicago, Chicago, IL 
      60612, USA.
FAU - Kumar, Sandeep
AU  - Kumar S
AD  - Department of Surgery, Division of Surgical Oncology, University of Illinois at 
      Chicago, Chicago, IL 60612, USA.
AD  - University of Illinois Hospital & Health Sciences System Cancer Center, 
      University of Illinois at Chicago, Chicago, IL 60612, USA.
FAU - Srivastava, Piush
AU  - Srivastava P
AUID- ORCID: 0000-0003-4646-9392
AD  - Department of Surgery, Division of Surgical Oncology, University of Illinois at 
      Chicago, Chicago, IL 60612, USA.
FAU - Jha, Saket
AU  - Jha S
AD  - Department of Surgery, Division of Surgical Oncology, University of Illinois at 
      Chicago, Chicago, IL 60612, USA.
FAU - Rana, Basabi
AU  - Rana B
AD  - Department of Surgery, Division of Surgical Oncology, University of Illinois at 
      Chicago, Chicago, IL 60612, USA.
AD  - University of Illinois Hospital & Health Sciences System Cancer Center, 
      University of Illinois at Chicago, Chicago, IL 60612, USA.
AD  - Jesse Brown VA Medical Center, Chicago, IL 60612, USA.
FAU - Rana, Ajay
AU  - Rana A
AD  - Department of Surgery, Division of Surgical Oncology, University of Illinois at 
      Chicago, Chicago, IL 60612, USA.
AD  - University of Illinois Hospital & Health Sciences System Cancer Center, 
      University of Illinois at Chicago, Chicago, IL 60612, USA.
AD  - Jesse Brown VA Medical Center, Chicago, IL 60612, USA.
LA  - eng
GR  - CA176846/CA/NCI NIH HHS/United States
GR  - CA178063/CA/NCI NIH HHS/United States
GR  - I01 BX005791/BX/BLRD VA/United States
GR  - R01 CA178063/CA/NCI NIH HHS/United States
GR  - R03 CA219764/CA/NCI NIH HHS/United States
GR  - CA216410/CA/NCI NIH HHS/United States
GR  - CA219764/CA/NCI NIH HHS/United States
GR  - I01 BX003296/BX/BLRD VA/United States
PT  - Journal Article
PT  - Review
DEP - 20230413
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10136566
OTO - NOTNLM
OT  - MAP4K4
OT  - cancer
OT  - immunity
OT  - inflammation
OT  - mitogen-activated protein kinase
COIS- The authors declare no conflict of interest.
EDAT- 2023/05/16 06:42
MHDA- 2023/05/16 06:43
PMCR- 2023/04/13
CRDT- 2023/05/16 01:13
PHST- 2023/03/16 00:00 [received]
PHST- 2023/04/11 00:00 [accepted]
PHST- 2023/05/16 06:43 [medline]
PHST- 2023/05/16 06:42 [pubmed]
PHST- 2023/05/16 01:13 [entrez]
PHST- 2023/04/13 00:00 [pmc-release]
AID - cancers15082272 [pii]
AID - cancers-15-02272 [pii]
AID - 10.3390/cancers15082272 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Apr 13;15(8):2272. doi: 10.3390/cancers15082272.